Bio-Techne (NASDAQ: TECH) reported Q1 EPS of $1.78, $0.06 worse than the analyst estimate of $1.84. Revenue for the quarter came in at $269.65 million versus the consensus estimate of $283.34 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.